Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
| Autor: | Gian Marco Corneo, Enrico Pogliani, Edoardo Marchesi, Carlo Gambacorti-Passerini, Pietro Pioltelli, Magda Verga, Rossella Barni, Fabio Rossi, Francesca Rossi |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
medicine.medical_treatment Fusion Proteins bcr-abl Chromosomal translocation Disease Biology Philadelphia chromosome Piperazines hemic and lymphatic diseases Leukemia Myelogenous Chronic BCR-ABL Positive medicine Tumor Cells Cultured Humans Aged Chemotherapy ABL breakpoint cluster region Hematology Middle Aged medicine.disease Fusion protein In vitro Pyrimidines Immunology Benzamides Cancer research Imatinib Mesylate Blast Crisis |
| Zdroj: | British journal of haematology. 112(4) |
| ISSN: | 0007-1048 |
| Popis: | STI571 (CGP57148B) is an inhibitor of BCR/ABL, the cause of chronic myeloid leukaemia (CML). A difference exists between CML patients in chronic phase, in which responses to STI571are durable, and patients in blast crisis, who generally experience only transient responses. Leukaemic cells from six CML patients from whom samples could be obtained during chronic phase and at the time of blast crisis (BC) were compared for sensitivity to STI571, using an in vitro assay. BC samples showed a sensitivity similar to that obtained during chronic phase, suggesting that no substantial intrinsic resistance to STI571 was present in BC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text